8914dcad-b703-4099-a5dd-edb9cedc104c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- IL6_JAK_STAT3_SIGNALING+0.600
- INFLAMMATORY_RESPONSE+0.600
- ANGIOGENESIS+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- COMPLEMENT+0.400
- IL2_STAT5_SIGNALING+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.300
- FATTY_ACID_METABOLISM-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- HEDGEHOG_SIGNALING-0.100
- HEME_METABOLISM-0.100
- MYC_TARGETS_V1-0.100
- NOTCH_SIGNALING-0.100
- PEROXISOME-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3J85TTZM | MPNST | — | 0.905 |
| 2 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.876 |
| 3 | 5a674268-79a8-4a30-a6db-a4fd0b83e208 | — | — | 0.869 |
| 4 | MBCProject_0734_T1K_RNA | — | C | 0.869 |
| 5 | BS_J1AB8PMA | Med | Medulloblastoma | 0.864 |
| 6 | s0112287 | — | — | 0.862 |
| 7 | BS_HJRTC9JQ | high-grade glioma | — | 0.861 |
| 8 | ERR2208908 | — | — | 0.860 |
| 9 | TCGA-AN-A0XW-01A-11R-A109-07 | — | C | 0.858 |
| 10 | BS_QH82PBMB | pilocytic astrocytoma | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |